The True Nature of Dementia: A System Failure

At its core, dementia is not a single disease, but a cascading failure of systems, a biomechanical and neurochemical bankruptcy that culminates in the collapse of the most complex structure in the known universe: the human mind. Far from being a mystery, its mechanisms are becoming increasingly well understood. The external manifestation—memory loss, confusion, the fading of personality—is the end result of five underlying pathologies that feed off each other in a destructive cycle:

The Five Key Pathologies

1. Vascular Insufficiency (The Hungry Brain): The brain, which consumes 25% of the body's oxygen and glucose, depends on an intricate network of microvessels for sustenance. With age, inflammation, and metabolic disease, these vessels harden, become permeable, and deteriorate. Blood flow decreases, and the brain begins to slowly "starve," a condition known as vascular dementia.
2. Metabolic Dysfunction (Type 3 Diabetes): The brain's primary fuel is glucose, but to use it, it needs to respond to insulin. In dementia, the brain becomes resistant to insulin. Neurons are surrounded by glucose but cannot absorb it; they are literally "starving in a room full of food." This condition is so prevalent that many scientists now refer to Alzheimer's as "type 3 diabetes."
3. Neuroinflammation (Friendly Fire): The brain has its own immune cells, microglia, whose job is to patrol and clean up. Triggered by systemic inflammation (diet, leaky gut, stress), these cells become hyperactive, attacking healthy neurons and releasing inflammatory cytokines that act like chemical "grenades," creating a chronic wildfire in the neurological neighborhood.
4. Proteinopathies (Garbage Accumulation): The well-known amyloid plaques and tau tangles are not the cause of the disease, but rather the symptom of a malfunctioning waste disposal system. The glymphatic system, which "cleans" the brain during deep sleep, becomes ineffective. Beta-amyloid (a protein that is normally cleared) accumulates outside neurons, disrupting communication. Tau protein, which stabilizes the internal structure of neurons, becomes tangled, suffocating them from within.
5. Neurotransmitter Imbalance (Cut Communication Lines): The neurons that produce acetylcholine, the key neurotransmitter for memory and learning, are often the first to die. The cholinergic system collapses. It's like cutting the Wi-Fi and phone lines in a major city; communication stops.

The Failure of Conventional Treatment: An Institutionalized Surrender

The conventional medical approach to dementia is, to a large extent, an admission of defeat. It focuses on the use of drugs like Aricept or Namenda, which attempt to mildly inhibit the enzyme that breaks down acetylcholine. This strategy is analogous to trying to extinguish a forest fire consuming five different pathologies with a water pistol. It is a pathetically inadequate solution that ignores the complexity of the problem.

This model is not only ineffective, but philosophically a surrender. It accepts the premise that the brain cannot be repaired and that the best that can be done is to slightly delay the inevitable decline. It is a profitable model of perpetual management, not a plan for cure or regeneration. Despair has been monetized, creating an industry that politely escorts people into darkness instead of giving them the tools to fight back.

The Comprehensive Protocol: A Siege on Disease

To achieve a biological victory, a comprehensive approach is needed, attacking each of the pathophysiological pillars of dementia simultaneously. It's not a single "magic bullet," but rather an orchestra of molecular interventions working synergistically to rebuild, cleanse, energize, and protect the brain. This protocol is designed to do precisely that, divided into strategic phases that address the root of the problem.

Phase 1: Reconstruction of the Neural Infrastructure (First 8 Weeks)

The first step is to lay the groundwork for repair. If the damaged "infrastructure" is not rebuilt, any further intervention will be futile. This phase focuses on providing the signals and materials necessary for neuronal regeneration and protection.

Essential Compounds for Repair

• Cerebrolysin: This compound is an elite "repair kit" for the brain. It's a cocktail of neurotrophic factors and peptides that crosses the blood-brain barrier and delivers precise instructions to repair neurons, promote synaptogenesis (the creation of new connections), and neurogenesis (the birth of new neurons). It acts as a "brain fertilizer," instructing the brain on how to rebuild itself.
• GHK-Cu (Copper Peptide): This peptide is a genetic reprogrammer. It activates over 4,000 genes responsible for tissue repair, reduces inflammation, and functions as a powerful antioxidant. It signals the body to enter "repair mode," activating all regeneration protocols, which is crucial for cerebral vascular health.
• BPC-157: The body's "master healer." It is essential for repairing the blood-brain barrier, the brain's "security fence." By sealing this barrier, it prevents toxins and inflammation from entering from the periphery, creating a safe environment for neuronal regeneration.

Phase 2: Cleaning and Energy Optimization (Next 2-3 Months)

With the infrastructure under reconstruction, the next step is to "clean up the mess" and "restore energy." Neurons die because they are suffocated by their own waste and lack the energy to function. This phase focuses on mitochondrial health and cellular detoxification, while introducing nootropic support.

Compounds for Mitochondrial Energy and Cognitive Function

• Methylene Blue: It's a "mitochondrial jet fuel." It improves the efficiency of the electron transport chain, supercharging ATP production. It's a powerful antioxidant and prevents the aggregation of tau proteins, clearing internal "blockages" in neurons.
• NAD+ and NMN: NAD+ is the "currency" of cellular energy. Its levels drop dramatically with age and disease. Supplementation with NAD+ and its precursor, NMN, replenishes this energy, providing the raw power that every repair process needs.
• MOTS-c: This mitochondrial-derived peptide is a "master regulator" of metabolic homeostasis. It improves insulin sensitivity and stimulates mitochondrial biogenesis (the creation of new "power plants").
• 5-amino-1MQ: Acts as a "cheat code" for cellular energy. It inhibits the NAD+-consuming enzyme NNMT, thus boosting NAD+ levels without the need for massive doses. It's a power multiplier for cellular energy.
• Nootropics (Racetams and Alpha-GPC): Compounds such as **Phenylpiracetam, Aniracetam, and Oxiracetam** enhance acetylcholine function and receptor sensitivity. Combined with **Alpha-GPC**, the precursor to acetylcholine, they act as a "software update" for neuronal communication, improving memory, focus, and mental energy.

Phase 3: Advanced Neurochemical and Metabolic Support (Month 5 onwards)

Once the structure is being repaired and energy is being restored, the final phase involves "launching the heavy artillery" to modulate neurochemical and metabolic functions, consolidating gains and providing long-term protection.

Compounds for Fine Modulation

• Retatrutide: The ultimate longevity peptide. It's a triple agonist that improves insulin sensitivity, reduces systemic inflammation, and repairs hypothalamic dysfunction. By repairing the body, it protects the brain.
• KPV: The "fire extinguisher" for neuroinflammation. It calms overactive microglia, the brain's immune cells that have gone rogue.
• Tesofensine: A monoamine reuptake inhibitor that increases levels of dopamine, norepinephrine, and serotonin, counteracting neurotransmitter deficits and providing a cognitive and mood boost.
• Fladrafinil: A wakefulness-promoting agent that combats the overwhelming fatigue that often accompanies dementia.
• Melanotan I: Beyond its effects on the skin, it has neuroprotective effects, improving mood and libido.
• Nicotine (patch): A potent agonist of the nicotinic acetylcholine receptor, which improves focus and has been shown to be highly neuroprotective.

The Synergy of the Protocol: Attacking from All Angles

This isn't just a list of supplements; it's a symphony orchestra. Synergy is key.

• **Phase 1** rebuilds the infrastructure and seals the barriers.
• **Phase 2** floods the system with clean energy and turns on the communication lines.
• **Phase 3** optimizes systemic metabolism and fine-tunes neurochemistry.

Together, they attack every facet of dementia's pathophysiology simultaneously: vascular insufficiency, metabolic dysfunction, neuroinflammation, waste buildup, and neurotransmitter imbalance. It's a comprehensive and coordinated assault.

Non-Negotiable Foundations: Diet, Fasting, Sleep, and Stimulation

This protocol is useless if the pillars of the lifestyle are ignored. They are non-negotiable:

• Hybrid Mediterranean/Ketogenic Diet: The brain in dementia is insulin resistant and cannot use glucose. It must be fueled with ketones. A diet high in healthy fats (avocado, olive oil, fatty fish), moderate protein, and almost zero carbohydrates is essential. Eliminating sugar and processed foods is a metabolic battle.
• 18/6 Fasting: A daily 18-hour fast triggers autophagy, the body's cellular cleansing process, and promotes ketosis.
• Deep sleep: This is when the brain's glymphatic system "washes away" metabolic waste. Deep sleep is mandatory. Peptides like DSIP can help restore circadian rhythms if needed.
• Daily Exercise: Walking and resistance training pump blood and oxygen to the brain and release BDNF, the neuronal "fertilizer".
• Cognitive Stimulation: The brain is a muscle. Learning a language, reading, doing puzzles, playing an instrument; these activities build new neural networks.

Dosage Protocol: Comprehensive Neuro-regenerative Support for Dementia and Alzheimer's

IMPORTANT: General Usage Considerations

Dementia and Alzheimer's are NOT inevitable sentences or a progressive decline where the best scenario is to "manage symptoms," but a cascading system failure - a biomechanical and neurochemical bankruptcy with well-defined mechanisms that culminates in the collapse of the most complex structure in the universe: the human mind. The five underlying pathologies that feed back into each other in a destructive cycle are: 1) Vascular insufficiency (brain "suffocating" due to deteriorated microvessels that reduce blood flow - vascular dementia), 2) Metabolic dysfunction (brain insulin resistance where neurons "starve to death in a room full of food" - "type 3 diabetes"), 3) Neuroinflammation (hyperactive microglia attacking healthy neurons, releasing inflammatory cytokines like "chemical grenades" creating a chronic forest fire), 4) Proteinopathies (failed glymphatic waste removal system allowing accumulation of beta-amyloid plaques and tau tangles that suffocate neurons), and 5) Neurotransmitter imbalance (collapse of the cholinergic system with death of acetylcholine-producing neurons - a key neurotransmitter for memory/learning - cutting "lines of communication"). Conventional treatment FAILS because it uses drugs like Aricept or Namenda that attempt to mildly inhibit the enzyme that breaks down acetylcholine—it's like "trying to put out a forest fire of five pathologies with a water pistol"—a pathetically inadequate solution that ignores complexity, is philosophically a surrender that accepts the brain cannot be repaired, and is a profitable model of perpetual management that monetizes despair. This comprehensive neuro-regenerative support protocol is designed NOT to "manage decline" but to execute an "all-out siege" that attacks every pathophysiological pillar of dementia simultaneously through an orchestra of molecular interventions working in synergy to: rebuild neuronal infrastructure, clear cellular clutter (plaques, tangles), optimize mitochondrial energy, and modulate neurochemical/metabolic function. CRITICAL: This is a complementary support protocol, NOT a substitute for neurological evaluation and conventional treatment. Patients with advanced dementia (particularly severe stages with complete functional loss, severe agitation, psychosis) MUST maintain close neurological/geriatric supervision. The protocol is implemented in three strategic, staggered phases: Phase 1 (Neural Infrastructure Rebuilding - first 8 weeks), Phase 2 (Mitochondrial Energy Cleansing and Optimization + Nootropic Support - next 2-3 months), and Phase 3 (Advanced Neurochemical and Metabolic Support - month 5+). Full implementation takes a minimum of 6-12 months to observe quantifiable neurological improvements: stabilization or improvement of cognitive function (memory, attention, executive function), reduction of behavioral symptoms (agitation, apathy, depression), and improvement in activities of daily living. The fundamentals of a ketogenic/Mediterranean diet (the brain with dementia is insulin-resistant and must be fueled with ketones), 18:6 fasting (triggers autophagy, clearing waste), deep sleep (the glymphatic system "washes" the brain), daily exercise, and cognitive stimulation are absolutely non-negotiable and represent 50% of the results—the protocol is USELESS without these pillars.

PHASE 1: REBUILDING OF THE NEURAL INFRASTRUCTURE (Weeks 1-8)

Pillar 1A: Elite Neurotrophic Factor - Brain Fertilizer

Cerebrolysin

• Dosage : As an "elite brain repair kit"—a cocktail of neurotrophic factors and peptides that crosses the blood-brain barrier, delivering precise instructions to repair neurons, promote synaptogenesis (the creation of new synaptic connections critical for memory and learning), and neurogenesis (the birth of new neurons in the hippocampus, a region devastated in Alzheimer's disease)—Cebrolysin acts as "brain fertilizer," instructing the brain on how to rebuild itself. In dementia/Alzheimer's, where massive neuronal death in critical regions (hippocampus, entorhinal cortex, temporal lobe) is progressive, Cerebrolysin provides exogenous trophic factors (BDNF-like, NGF-like, CNTF-like) that these neurons desperately need for survival and regeneration. STRONG EVIDENCE : Multiple clinical studies show that Cerebrolysin improves cognition in vascular dementia and Alzheimer's disease, with effects that persist for months post-treatment. In the context of established dementia where aggressive neuroprotection and potential regeneration of residual cognitive circuits are required, doses of 10–30 ml per administration are recommended, depending on severity. For mild dementia (MoCA 18–25, MMSE 20–26) with subtle cognitive deficits but preserved functionality, 10–20 ml per session may be appropriate. For moderate-to-severe dementia (MoCA <18, MMSE <20) with significant cognitive impairment and dependence for activities of daily living (ADLs), 20–30 ml per session provides more robust neurotrophic saturation.

• Frequency of administration : Cerebrolysin is administered by intravenous (IV) or intramuscular (IM) injection, typically in intensive cycles. Standard protocol for dementia : 5 consecutive days per week for 4 weeks (20 sessions total), followed by an 8-12 week break, then repeat the cycle. IV administration (preferred for maximum bioavailability): Dilute the dose (10-30 ml) in 100-250 ml of normal saline and infuse slowly over 15-30 minutes. Slow infusion minimizes adverse effects (transient facial warmth, mild dizziness). IM administration (alternative if IV is not available): Divide the dose into 2-3 sites (maximum 5 ml per site), rotating sites (buttocks, lateral thighs). Timing: Preferably in the morning to take advantage of the window of daytime neuronal activity and daytime learning consolidation.

• Cycle duration : Cerebrolysin is used in 4-week cycles (20 sessions) as an intensive neurotrophic rebuilding phase, followed by an extended 8-12 week break to allow consolidation of induced structural changes (new synapses, improved neuronal survival, potential neurogenesis). During the active cycle, progressive improvements are observed in: cognitive function (improved episodic memory, sustained attention, processing speed), functionality in activities of daily living (improved instrumental ADLs such as medication management and finances), behavioral symptoms (reduced apathy and agitation), and potentially a slowing of progression (compared to the expected trajectory without treatment). For chronic dementia, cycles can be repeated 2-3 times per year (every 4-6 months) as long-term neurotrophic maintenance with the aim of stabilizing or slowing decline. EVIDENCE : Meta-analyses show that Cerebrolysin improves cognitive and functional outcomes in dementia with a moderate effect size, particularly in vascular dementia where the ischemia/hypoxia component is prominent.

Pillar 1B: Genetic Reprogramming and Cerebrovascular Health

GHK-Cu (Copper Peptide)

• Dosage : A dose of 200-300 mcg per administration is recommended. For general neuroprotective support in mild-to-moderate dementia, 200 mcg daily may be sufficient. For dementia with a prominent vascular component or severe neuroinflammation (rapid progression, severe behavioral symptoms), 300 mcg daily or 200 mcg twice daily provides more pronounced anti-inflammatory/vascular effects.

• Frequency of administration : GHK-Cu is administered by subcutaneous injection, typically once daily (200–300 mcg) or twice daily (200 mcg each time) if maximum saturation is required. Morning administration is convenient, although specific timing is less critical than consistency. The injection can be given at any subcutaneous site; rotate appropriately to minimize local irritation.

• Cycle duration : GHK-Cu can be used for 8-12 week cycles as an intensive anti-inflammatory and vascular reprogramming phase. During this period, the following are observed: reduction of neuroinflammation markers (if measured), improvement of cerebral perfusion (particularly in vascular dementia), potential improvement of behavioral symptoms (inflammation-mediated agitation and irritability), and subjective improvement in mental clarity. After the cycle, a 4-8 week break is recommended. For chronic dementia, 8-12 week cycles followed by 4-6 weeks of rest can be repeated indefinitely as long-term anti-inflammatory/vascular support.

Pillar 1C: Blood-Brain Barrier Repairer - Guardian of the Brain

BPC-157

• Dosage : A dose of 250–500 mcg per administration is recommended. For mild-to-moderate dementia without evidence of severe peripheral inflammation, 250 mcg twice daily may be appropriate. For dementia with systemic inflammatory syndrome (elevated hsCRP, cytokines), gastrointestinal symptoms (common in dementia—constipation, dysphagia), or rapid progression, 500 mcg twice daily provides more robust blood-brain barrier repair and more pronounced anti-inflammatory effects.

• Frequency of administration : BPC-157 is administered by subcutaneous injection, typically twice daily (morning and evening) for stable plasma levels and continuous blood-brain barrier (BBB) ​​effects. Administration can be at any subcutaneous site; rotate appropriately.

• Cycle duration : BPC-157 can be used in 8-12 week cycles as a blood-brain barrier (BBB) ​​repair and neuroinflammation control phase. During this period, the following are observed: potential improvement in cognitive function (reduction of "brain fog" due to less inflammatory factors entering the brain), improvement in comorbid GI symptoms (common in dementia due to autonomic dysfunction), reduction in agitation/irritability (mediated by inflammation), and improvement in overall well-being. After the cycle, a 4-8 week break is recommended. For chronic dementia, cycles can be repeated indefinitely.

PHASE 2: CLEANSING AND ENERGY OPTIMIZATION + NOOTROPIC SUPPORT (Weeks 9-20)

Pillar 2A: Mitochondrial Jet Fuel and Anti-Tau

Methylene Blue

• Dosage : The dose is key – low doses (<1 mg/kg) are therapeutic (antioxidant, anti-tau, pro-mitochondrial), while high doses (>5 mg/kg) are pro-oxidant. For neuroprotection in dementia, LOW doses are recommended: 0.5–1 mg/kg daily (e.g., for a 70 kg person, 35–70 mg daily). Typically, 50–100 mg daily in capsules or oral solution.

• Frequency of administration : Methylene Blue is administered orally, once a day with or without food. Morning administration is common (may be mildly stimulating). IMPORTANT WARNING : Methylene Blue colors urine a bright blue-green (harmless effect but alarming if not anticipated - explain to patient/caregiver). It may also color stools. The effect is temporary and reversible.

• Duration of treatment : Methylene blue can be used indefinitely as chronic mitochondrial and anti-tau support in dementia. Some protocols use 5 days on, 2 days off weekly, although continuous use is also appropriate. For established dementia, long-term use (6-12+ months) is necessary to observe benefits against progression.

Pillar 2B: Cellular Energy Currency Replenishment

NAD+ and NMN (Nicotinamide Mononucleotide)

• Dosage : Recommended: Oral NMN : 500-1000 mg daily (sublingual form for better absorption - many products come in sublingual powder). IV NAD+ (if available): 250-500 mg by infusion, 1-2 times per week during the intensive phase, then weekly or bi-weekly maintenance.

• Frequency of administration : Oral NMN : Once daily on an empty stomach in the morning (sublingual - hold under the tongue for 60-90 seconds before swallowing). IV NAD+ : Slow infusion over 2-4 hours (rapid infusion causes facial flushing, severe nausea, discomfort - it must be SLOW), 1-2 times per week intensive phase, then weekly or bi-weekly maintenance depending on access and cost.

• Duration of treatment : NMN can be used indefinitely as baseline supplementation in dementia. IV NAD+ is typically used in intensive 4-8 week cycles (8-16 total infusions), followed by maintenance with less frequent infusions (1-2 times per month) or a transition to oral NMN only. During use, the following are observed: improvement in subjective energy, potential improvement in cognitive function (particularly attention and processing speed, which depend on brain energy), and improvement in overall vitality.

Pillar 2C: Master Mitochondrial Regulator

MOTS-c

• Dosage : A dose of 10-15 mg per administration is recommended.

• Frequency of administration : MOTS-c is administered by subcutaneous injection, typically 2-3 times per week (e.g., Monday, Wednesday, Friday). Morning timing is common.

• Cycle duration : MOTS-c can be used for 12-20 week cycles or even for long-term continuous use. During use, the following are observed: improved brain energy, potential improvement in cerebral glucose metabolism (important in type 3 diabetes), and indirect improvement in cognitive function via metabolic optimization. For chronic dementia, it can be used indefinitely given its excellent safety profile.

Pillar 2D: NAD+ Multiplier - Energy Cheat Code

5-Amino-1MQ

• Dosage : In dementia where NAD+ is depleted, a dose of 50-100 mg daily is recommended.

• Frequency of administration : 5-Amino-1MQ is administered orally (typically in capsules) or by subcutaneous injection, once a day. Oral route : Take on an empty stomach in the morning for maximum absorption. Subcutaneous route (if available): 50-100 mg daily by morning injection.

• Cycle duration : 5-Amino-1MQ can be used for 12-20 week cycles or for long-term continuous use. During use, the following are observed: a dramatic increase in endogenous NAD+ (synergy with NMN - both increase NAD+ through complementary pathways), improved mitochondrial function, and potential cognitive enhancement. For dementia, it can be used indefinitely.

Pillar 2E: Software Update for Neural Communication

Racetams (Phenylpiracetam, Aniracetam, Oxiracetam) + Alpha-GPC

• Dosage : As nootropics that improve acetylcholine function (the key neurotransmitter for memory/learning, whose system collapses in dementia—one of the five core dementia pathologies) and receptor sensitivity, acting as a "software update" for neuronal communication, racetams combined with Alpha-GPC (a direct precursor of acetylcholine) are essential. Phenylpiracetam : 100–200 mg once or twice daily (stimulant, avoid late in the evening—may cause insomnia). Aniracetam : 750–1500 mg divided into two or three daily doses. Oxiracetam : 800–1200 mg divided into two or three daily doses. Alpha-GPC : 300–600 mg once or twice daily (provides choline for acetylcholine synthesis—without choline, racetams may cause headaches due to cholinergic deficiency).

• Frequency of administration : Phenylpiracetam : 1-2 times daily, last dose before 4 PM (long half-life, may cause insomnia). Aniracetam : 2-3 times daily with meals (fat-soluble - absorption enhanced with fat). Oxiracetam : 2-3 times daily with or without meals. Alpha-GPC : 1-2 times daily, typically in conjunction with racetam doses.

• Duration of treatment : Racetams can be used indefinitely in dementia as chronic cholinergic support, or in cycles of 8–12 weeks on, 2–4 weeks off. Phenylpiracetam specifically may develop tolerance—cycle more frequently (4–6 weeks on, 2 weeks off) or use only on days requiring maximum cognitive stimulation. During use, the following are observed: improved memory (particularly the formation of new memories), improved attention/concentration, improved processing speed, and potential mood improvement (aniracetam has anxiolytic properties).

PHASE 3: ADVANCED NEUROCHEMICAL AND METABOLIC SUPPORT (Month 5+)

Pillar 3A: Systemic Metabolic Reprogramming - Longevity Peptide

Retatrutida

• Dosage : In dementia, particularly with metabolic comorbidities (obesity, type 2 diabetes, metabolic syndrome), a conservative dose is recommended: 1-2 mg once a week (lower doses than in diabetes or obesity since the primary objective is metabolic neuroprotection, not aggressive weight loss).

• Frequency of administration : Retatrutide is administered by subcutaneous injection once a week, on the same day each week. Given the potential for nausea (30-50% of users), many prefer to administer it Friday/Saturday night. It can be administered independently of meals. Rotate injection sites weekly.

• Cycle duration : Retatrutide can be used in 12-16 week cycles as a systemic metabolic optimization phase that benefits the brain. During use, the following are observed: improved insulin sensitivity (benefiting cerebral glucose metabolism), reduced systemic inflammation (hsCRP may be reduced by 40-60%), weight loss if overweight/obese (beneficial - obesity is a major risk factor for dementia), and potential improvement in cognitive function indirectly via metabolic optimization. After the cycle, taper the dose (50% for 2-3 weeks, then discontinue). For dementia with a prominent metabolic component, cycles may be repeated.

Pillar 3B: Neuroinflammation Extinguisher - Microglia Calming

KPV

• Dosage : As a "fire extinguisher" peptide for neuroinflammation that calms overactive microglia (the brain's immune cells that, in dementia, become "rogue," attacking healthy neurons and releasing inflammatory cytokines such as IL-1β, IL-6, and TNF-α, which perpetuate neurodegeneration), KPV is a specific tool for controlling brain inflammation. A dose of 500–1000 mcg per administration is recommended.

• Frequency of administration : KPV is administered by subcutaneous injection, typically once or twice daily depending on the severity of neuroinflammation. Common protocol: 500-1000 mcg in the morning, optionally a second dose at night if inflammation is severe.

• Cycle duration : KPV can be used for 8-12 week cycles as an intensive neuroinflammation control phase. After the cycle, a 4-week break is required. For dementia with prominent neuroinflammation (rapid progression, severe behavioral symptoms), cycles can be repeated (8 weeks on, 4 weeks off).

Pillar 3C: Dopaminergic and Serotonergic Support

Tesofensine

• Dosage : As a monoamine reuptake inhibitor that increases synaptic levels of dopamine, norepinephrine, and serotonin, tesofensine counteracts neurotransmitter deficiencies (common in dementia—not only is acetylcholine compromised, but also dopamine and serotonin, contributing to apathy, depression, and fatigue), providing cognitive and mood enhancement. CRITICAL : Tesofensine is potent—it can cause tachycardia, hypertension, and insomnia—use with caution in the elderly. For dementia, an ultra-conservative dose of 0.25 mg once daily is recommended (start with this dose; do not increase without careful assessment of tolerance for 2–4 weeks).

• Frequency of administration : Tesofensine is administered orally, once a day strictly in the early morning (its long half-life may cause insomnia if taken late). Take with food to minimize nausea.

• Cycle duration : Tesofensine can be used for 8-12 week cycles as symptomatic support for apathy/depression/fatigue while other regenerative interventions take effect. STRICT MONITORING IN THE ELDERLY : Blood pressure and heart rate should be monitored weekly—if BP >140/90 or HR >90 bpm at rest, discontinue immediately. After the cycle, take a 4-8 week break.

Pillar 3D: Vigilance Promoters - Combatting Fatigue and Apathy

Fladrafinil

• Dosage : 30-60 mg in the morning.

• Frequency of administration : Administer orally once a day strictly early in the morning (6-8 AM) to avoid insomnia. It can be taken with or without food.

• Cycle duration : They can be used as needed (days with greater fatigue/apathy) or daily during periods when these symptoms are particularly debilitating.

Pillar 3E: Neuroprotection and Quality of Life

Melanotan I

• Dosage : As a melanocyte-stimulating hormone analogue that, beyond its skin effects, has neuroprotective effects (activation of melanocortin receptors in the brain), improves mood (antidepressant), and enhances libido (a quality-of-life aspect frequently affected in dementia but rarely addressed), Melanotan I is a unique tool. A dose of 250-500 mcg 2-3 times per week is recommended.

• Frequency of administration : Melanotan I is administered by subcutaneous injection, 2-3 times per week (e.g., Monday, Wednesday, Friday). Nighttime administration minimizes transient adverse effects (mild post-injection nausea typically occurs in the first 30-60 minutes).

• Cycle duration : Melanotan I can be used in cycles of 8-12 weeks, followed by a 4-6 week break. ADVERSE EFFECTS : Skin darkening (melanogenesis effect - reversible after discontinuation but may take months), transient nausea, increased libido.

Pillar 3F: Nicotinic Agonist - Validated Neuroprotection

Nicotine (Transdermal Patch)

• Dosage : As a potent agonist of the nicotinic acetylcholine receptor that improves focus and attention, and has been shown to be highly neuroprotective (epidemiological studies show that smokers have a lower risk of Alzheimer's disease—the protective effect of nicotine, not smoke; studies in animal models show that nicotine reduces amyloid plaque formation and improves cognition), nicotine in patch form (smoke-free, carcinogen-free) is a valuable tool in dementia. Transdermal patches of 7–14 mg daily are recommended for non-smokers (start with 7 mg).

• Frequency of administration : Transdermal patch applied once a day to a clean, hairless area (upper arm, torso), rotating sites daily. Apply in the morning, remove before going to sleep (nicotine may cause insomnia, vivid dreams if used 24 hours a day).

• Duration of treatment : Nicotine can be used indefinitely as a long-term neuroprotective strategy in dementia. WARNING : It is addictive – users with no history of smoking (or caregivers applying the patch to the patient) should be aware of the potential for dependence. Abrupt discontinuation may cause irritability and anxiety in the user – gradually reduce the dose if discontinuing (go from 14 mg to 7 mg over 2 weeks, then discontinue).

COMPLETE INTEGRATED PROTOCOL: Strategic Implementation in 3 Phases

Optimal Sequence (24 Week - 6 Month Program)

PHASE 1: INFRASTRUCTURE REBUILDING (Weeks 1-8)

Weeks 1-2 (Assessment and Preparation):

• Comprehensive cognitive assessment: MoCA or MMSE, functional assessment (basic and instrumental ADLs), behavioral assessment, quality of life
• Laboratory panel: Complete blood count, liver/kidney function, TSH (hypothyroidism mimics dementia), B12/folate (deficiency causes reversible cognitive impairment), homocysteine, hsCRP, glucose/insulin, lipid profile
• Neuroimaging if not already done: Brain MRI (to assess atrophy, infarcts, hemorrhages)
• Implement the fundamentals STRICTLY: Hybrid ketogenic/Mediterranean diet, 18:6 fasting, daily exercise (minimum 30-minute walk), cognitive stimulation
• Do not initiate peptides yet - establish a stable baseline and fundamentals

Weeks 3-6 (Start of Neurotrophic Reconstruction):

• Initiate Cerebrolysin : 4-week cycle (5 days/week, 20 total sessions) at 10-20 ml IV or IM depending on severity and access
• Initiate BPC-157 : 250-500 mcg twice daily subcutaneously
• Start GHK-Cu : 200-300 mcg 1x/day subcutaneous
• Continue with the fundamentals strictly (they make up 50% of the results)
• Monitoring: Tolerance, adverse effects, weekly informal cognitive assessment (caregiver reports changes in memory, attention, functionality)

Weeks 7-8 (Phase 1 Consolidation):

• Cerebrolysin : Finished (4-week cycle completed)
• Continue BPC-157 and GHK-Cu
• Progress assessment (week 8): Formal MoCA/MMSE, functionality, behavioral symptoms, laboratory if accessible (inflammatory markers)
• Objective : Neural repair fundamentals established, blood-brain barrier repaired, neuroinflammation reduced, preparation for energy phase

PHASE 2: ENERGY AND NOOTROPIC OPTIMIZATION (Weeks 9-20)

Weeks 9-12 (Add Mitochondrial Support):

• Continue BPC-157 and GHK-Cu (or begin tapering if improvement is excellent)
• Start Methylene Blue : 50-100 mg daily orally (warn about blue-green urine)
• Start NMN : 500-1000 mg daily oral sublingual
• Start MOTS-c : 10-15 mg 2-3x/week subcutaneous
• Start 5-Amino-1MQ : 50-100 mg daily orally
• Consider IV NAD+ if available: 250-500 mg 1-2 times/week
• Objective : Optimized mitochondrial function, restored brain energy

Weeks 13-16 (Add Cholinergic Nootropic Support):

• Continue mitochondrial components
• Start Aniracetam : 750-1500 mg daily divided into 2-3 doses with meals
• Start Alpha-GPC : 300-600 mg 1-2x/day
• Consider adding Oxiracetam : 800-1200 mg daily divided if response to aniracetam is good
• Consider Phenylpiracetam : 100-200 mg in the morning (only if there are no cardiovascular problems - it is a stimulant)
• Comprehensive assessment (week 16): MoCA/MMSE, functionality, behavioral symptoms, quality of life, laboratory
• Objective : Optimized neuronal communication, improved memory, sustained attention

Weeks 17-20 (Phase 2 Consolidation):

• Continue all components, adjusting dosage according to response
• Repeat the Cerebrolysin cycle (4 weeks, 20 sessions) if the initial response was positive and 12 weeks have passed since the first cycle
• Objective : To consolidate energy and cognitive improvements

PHASE 3: ADVANCED METABOLIC AND NEUROCHEMICAL MODULATION (Weeks 21-24+)

Weeks 21-24 (Add Systemic and Symptomatic Optimization):

• Base regenerative components: Evaluate whether BPC-157/GHK-Cu can be reduced or cycled off, or continued at maintenance dosage
• Mitochondrial/Nootropic Components: Continue
• Initiate Retatrutide : 1-2 mg once a week subcutaneously (if there is a metabolic component: overweight, diabetes, metabolic syndrome)
• Initiate KPV : 500-1000 mcg 1-2x/day subcutaneously (if there is persistent neuroinflammation, severe behavioral symptoms)
• Initiate Tesofensine : 0.25 mg orally in the morning (ONLY if there are no cardiovascular contraindications, with strict BP/HR monitoring)
• Consider Nicotine Patch : 7 mg daily transdermal
• Consider Fladrafinil : 30-60 mg orally in the morning (if fatigue/apathy are prominent)
• Consider Melanotan I : 250-500 mcg 2-3 times/week subcutaneously (if mood and motivation are problematic)
• Final assessment (week 24): Complete MoCA/MMSE, full functionality, behavioral symptoms, quality of life, complete laboratory
• Success criteria : MoCA/MMSE stabilization (no deterioration = success in dementia), improvement in ADL functionality, reduction of behavioral symptoms (agitation, apathy, depression), improvement in quality of life reported by patient/caregiver

POST-Protocol (Long-Term Maintenance - Indefinite):

Continuous components indefinitely:

• Methylene Blue: 50-100 mg daily
• NMN: 500-1000 mg daily
• MOTS-c: 2-3x/week
• 5-Amino-1MQ: Daily or cyclical (12 weeks on, 4 weeks off)
• Racetams + Alpha-GPC: Daily (aniracetam, oxiracetam) or cyclical (phenylpiracetam 4-6 weeks on, 2 off)
• Nicotine Patch: Daily indefinitely
• PRINCIPLES : Diet, fasting, exercise, cognitive stimulation - PERMANENT

Cyclic components:

• Cerebrolysin: 4-week cycle (20 sessions) every 4-6 months as a neurotrophic "booster"
• BPC-157, GHK-Cu: Cycles of 8-12 weeks every 4-6 months
• Retatrutide, KPV, Tesofensine: Cycles according to symptomatic/metabolic need
• Fladrafinil, Melanotan I: Use as needed

NON-NEGOTIABLE PRINCIPLES - CRITICAL FOR RESULTS

MEDITERRANEAN/KETOGENIC HYBRID DIET - OPTIMAL BRAIN FUEL

Critical Rationale : The brain with dementia is insulin resistant and CANNOT use glucose efficiently - it must be fueled with KETONES (alternative fuel produced when the body burns fat in the absence of carbohydrates).

Macronutrients:

• Healthy fats: 60-75% of calories
  • Extra virgin olive oil (4-6 tablespoons daily)
  • Avocado (1-2 daily)
  • Wild fatty fish (salmon, sardines, anchovies, herring) - 4-5x/week (omega-3 EPA/DHA are powerful neuroprotective agents)
  • Nuts, seeds (moderation - calorie density)
  • Coconut oil/MCT (medium chain triglycerides are quickly converted into ketones - 1-2 tablespoons daily)
• Protein: 15-20% of calories (1-1.2 g/kg) - enough to preserve muscle without excess
• Carbohydrates: <50g net daily (ketosis) or <100g (low carb)
  • Sources: Non-starchy vegetables (broccoli, spinach, kale, cauliflower, asparagus, zucchini)
  • Berries (blueberries, strawberries, raspberries) - small portions (30-50g) - rich in neuroprotective antioxidants

Completely remove:

• Sugars: All without exception
• Refined carbohydrates: Bread, pasta, rice, cereals, baked goods
• Seed oils: Soybean, canola, corn, sunflower (pro-inflammatory)
• Processed foods: All

Specific Neuroprotective Foods:

• Turmeric: 500-1000 mg twice daily with piperferin (crosses the blood-brain barrier, reduces amyloid, potent anti-inflammatory)
• Green tea: 2-3 cups daily (neuroprotective EGCG)
• Dark chocolate 85%+: 20-30g daily (neuroprotective flavonoids)

18:6 INTERMITTENT FASTING - AUTOPHAGY AND KETOSIS

Rationale : An 18-hour fast triggers autophagy (a cellular cleaning process that eliminates amyloid plaques and tau tangles - the "garbage disposal system" that fails in dementia) and promotes deep ketosis.

Protocol :

• Feeding window: 12 PM - 6 PM (18 hours of daily fasting)
• During fasting: Water, black coffee, unsweetened tea only
• First meal (12 PM): Rich in fats and protein
• Second meal (6 PM): Similar, ensure sufficient total caloric intake

Benefits for Dementia :

• Maximum autophagy (cleaning of misfolded proteins)
• Deep ketosis (alternative brain fuel)
• Reduction of inflammation
• Improved insulin sensitivity

DEEP SLEEP - GLYMPHATIC SYSTEM AND MEMORY CONSOLIDATION

Background : The brain's glymphatic system (the drainage system that "washes" the brain by removing metabolic waste, including beta-amyloid) functions ONLY during deep sleep. Without deep sleep, the brain "drowns" in its own waste.

Protocol :

• Duration: 7-8 hours at night
• Fixed schedule: Go to bed/wake up at the same time ±30 min
• Environment: Total darkness, cool temperature (16-18°C), silence
• Hygiene: Avoid screens 2 hours before sleep, avoid caffeine after 2 PM, eat a light dinner 3 hours before sleep

If Sleep is Problematic :

• Consider DSIP (Delta Sleep-Inducing Peptide): 100-300 mcg subcutaneously at night - restores sleep architecture, dramatically increases deep sleep
• Melatonin: 0.5-3 mg at night (lower doses are more effective than higher doses)
• Magnesium: 400-600 mg (glycinate) nighttime

DAILY EXERCISE - BDNF AND CEREBRAL PERFUSION

Rationale : Exercise releases BDNF (Brain-Derived Neurotrophic Factor - "brain fertilizer" that promotes neurogenesis and synaptogenesis) and improves cerebral perfusion (blood flow to the brain).

Minimum Protocol :

• Walking: 30-60 mins daily (moderate intensity, ability to maintain a conversation)
• Resistance training: 2-3 times/week (preserves muscle, improves metabolism)
• Tai Chi or Yoga: 2-3 times/week (improves balance, reduces falls, meditative component reduces stress)

Adaptation for Advanced Dementia :

• If mobility is limited: Seated exercises, short assisted walks
• Supervision to prevent falls

COGNITIVE STIMULATION - USE OR LOSS

Rationale : The brain is a muscle – “use it or lose it.” Cognitive stimulation builds cognitive reserve and new neural networks that compensate for damaged areas.

Daily Activities :

• Reading: 30-60 min daily (books, newspapers)
• Puzzles: Sudoku, crosswords, memory games
• Learning: New language, musical instrument, new skill
• Socialization: Conversations, board games, group activities
• Reminiscence: Photo albums, stories from the past (reinforces identity)

MONITORING AND EVALUATION

Comprehensive Dementia Panel (Baseline, Week 8, 16, 24, then Quarterly):

Cognitive Assessment:

• MoCA (Montreal Cognitive Assessment): Sensitive screening (30 points maximum, <26 suggests impairment)
• MMSE (Mini-Mental State Examination): Standard (30 points, <24 suggests dementia)
• Specific domains : Episodic memory, attention, executive function, language, orientation
• Objective : Stabilization (no deterioration) or improvement

Functional Assessment:

• Basic Activities of Daily Living (BADL): Dressing, bathing, eating, continence, mobility
• Instrumental Activities of Daily Living (IADL): Telephone, shopping, finance, medication, transportation
• Objective : Preservation or improvement of independence

Behavioral Assessment:

• NPI (Neuropsychiatric Inventory): Agitation, depression, anxiety, apathy, psychosis
• Objective : Reduction of behavioral symptoms

Quality of Life:

• QOL-AD : Alzheimer's-specific quality of life
• Patient and Caregiver Report

Laboratory:

• Inflammatory markers (hsCRP), liver/kidney function (safety), TSH, B12

Success Criteria:

• Cognitive stabilization (stable MoCA/MMSE = GREAT success in dementia)
• Functional improvement (recovery of instrumental ADLs)
• Behavioral reduction (less agitation, depression, apathy)
• Improved quality of life
• Slowing of progression (compared to expected trajectory)

CRITICAL WARNINGS

Contraindications:

• Untreated reversible secondary dementia (hypothyroidism, B12 deficiency, normal pressure hydrocephalus - treat cause first)
• Severe uncontrolled cardiovascular disease
• Severe uncontrolled active psychosis

Interactions:

• Tesofensine + MAOIs: CONTRAINDICATED (serotonin syndrome)
• Methylene Blue + MAOIs: CONTRAINDICATED
• Nicotine + Anticholinergics: Opposing effects

Precautions for the Elderly:

• Frailty increases the risk of adverse effects
• Common polypharmacy - thoroughly review interactions
• More frequent monitoring (weekly for the first 4-8 weeks)

CONCLUSION: FROM MANAGING DECLINE TO FIGHTING FOR REGENERATION

Dementia is NOT an inevitable sentence.

It is a failure of systems with defined mechanisms that can be attacked.

This 3-phase protocol executes "total siege":

Phase 1 rebuilds neural infrastructure. Phase 2 floods with clean energy and turns on communication. Phase 3 optimizes metabolism and fine-tunes neurochemistry.

The synergy attacks all 5 pathologies simultaneously:

• Vascular insufficiency
• Metabolic dysfunction
• Neuroinflammation
• Proteinopathies
• Neurotransmitter deficiency

The fundamentals are 50% results - NON-NEGOTIABLE.

It's not about adding years to life - it's about adding LIFE to years.

Restore the essence of a person: memory, wit, identity.

The tools exist.

The will to fight is yours.

Take action.